Will COMPASS Point to a New Direction in Thrombotic Risk Reduction in Patients With Stable Cardiovascular Disease?

Circulation. 2018 Aug 28;138(9):858-860. doi: 10.1161/CIRCULATIONAHA.118.035405.

Authors

William E Boden¹, Deepak L Bhatt²

Affiliations

¹ VA New England Healthcare System, Boston University School of Medicine, MA (W.E.B.).
² Brigham and Women's Heart & Vascular Center, Harvard Medical School, Boston, MA (D.L.B.).

PMID: 30354448
DOI: 10.1161/CIRCULATIONAHA.118.035405

No abstract available

Keywords: anticoagulants; coronary artery disease; peripheral artery disease.

MeSH terms

Acute Coronary Syndrome / blood
Acute Coronary Syndrome / mortality
Acute Coronary Syndrome / therapy*
Aspirin / administration & dosage*
Aspirin / adverse effects
Drug Therapy, Combination
Factor Xa Inhibitors / administration & dosage*
Factor Xa Inhibitors / adverse effects
Hemorrhage / chemically induced
Humans
Percutaneous Coronary Intervention* / adverse effects
Percutaneous Coronary Intervention* / mortality
Peripheral Arterial Disease / blood
Peripheral Arterial Disease / drug therapy*
Peripheral Arterial Disease / mortality
Platelet Aggregation Inhibitors / administration & dosage*
Platelet Aggregation Inhibitors / adverse effects
Risk Assessment
Risk Factors
Rivaroxaban / administration & dosage*
Rivaroxaban / adverse effects
Thrombosis / mortality
Thrombosis / prevention & control*
Treatment Outcome

Substances

Factor Xa Inhibitors
Platelet Aggregation Inhibitors
Rivaroxaban
Aspirin